治疗中央血清性胆色素变异的埃普莱伦:这种治疗还有空间吗?
Irini Chatziralli1, Chrysa Agapitou1, Stamatios Lampsas1
12nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Biomedicines
|February 27, 2026
概括
口服eplerenone有效地治疗中央血清性胆色素变异症 (CSCR),改善视力和解决大多数患者的液体. 这种安全的治疗方案在12个月内在急性和慢性CSCR病例中显示出显著的结果.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 中央血清性胆色素变异症 (CSCR) 是一种影响视力的疾病.
- 目前对CSCR的治疗选择可能有局限性.
- 评估新型治疗剂对于管理CSCR至关重要.
研究的目的:
- 评估口服eplerenone在治疗急性和慢性中央血清性胆色素变异症 (CSCR) 的疗效和安全性.
- 为了比较用eplerenone治疗的患者与接受观察的患者的结果.
主要方法:
- 一项前性研究涉及43名被诊断患有CSCR和下液的患者.
- 患者被随机分配,接受口服eplerenone或观察.
- 测量结果包括最佳校正的视力敏度 (BCVA),光学连贯性断层扫描 (OCT) 来检测下液 (SRF) 解析度,以及12个月的光素血管扫描 (FA).
主要成果:
- 在12个月后,65.2%的eplerenone患者实现了SRF解决,而对照组的25% (p=0.008).
- 与对照组不同的是,eplerenone组在6个月和12个月后显示出统计学上显著的BCVA改善 (p<0.001).
- 没有报告显著的眼部或全身不良事件,除了口腔干燥在eplerenone接受者的30.4%.
结论:
- 口服eplerenone是一种安全有效的治疗急性和慢性CSCR.
- 在CSCR患者中,eplerenone促进了显著的下液分辨率和视力敏度的改善.
- 这项研究支持eplerenone作为一种可行的治疗替代方案来管理CSCR.
相关概念视频
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment
1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
511
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511
Nephrotic Syndrome II : Assessment and Medical Management
279
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
279
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K


